Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.84 |
| ▸ | LPL | P06858 | 3/20 | 0.84 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.84 |
| ▸ | CA1 | P00915 | 3/20 | 0.61 |
| ▸ | MGLL | Q99685 | 1/20 | 0.61 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.59 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.59 |
| ▸ | ORAI3 | Q9BRQ5 | 1/20 | 0.59 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA5A | P35218 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tolyl Boronic Acid SCHEMBL129197 | 0.92 | CA2 (1.00) | CA2LPLLIPGCA1MGLL | |
| Tolyl Boronic Acid SCHEMBL5600068 | 0.92 | CA2 (1.00) | CA2LPLLIPGCA1MGLL | |
| Tolyl Boronic Acid SCHEMBL8889893 | 0.89 | CA2 (0.94) | CA2LPLLIPGCA1MGLL | |
| Tolyl Boronic Acid SCHEMBL1992708 | 0.89 | CA2 (0.94) | CA2LPLLIPGCA1MGLL | |
| Tolyl Boronic Acid SCHEMBL19268206 | 0.89 | CA2 (0.94) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL470006 | 0.87 | CA2 (0.64) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL13667445 | 0.86 | CA2 (0.78) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL806835 | 0.86 | CA2 (0.78) | CA2LPLLIPGCA1MGLL | |
| SCHEMBL18394607 | 0.86 | CA2 (0.78) | CA2LPLLIPGCA1MGLL | |
| Tolyl Boronic Acid SCHEMBL3395642 | 0.84 | CA2 (0.84) | CA2LPLLIPGCA1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250120252-A1 | MATERIALS FOR FORMING A NUCLEATION-INHIBITING COATING AND DEVICES INCORPORATING SAME | OTI LUMIONICS INC. (CA) | 2025-04-10 | — | — | US | disclosed |
| US-12268092-B2 | Photoelectric conversion element, imaging element, optical sensor, material for photoelectric conversion element, and compound | FUJIFILM CORPORATION (JP) | 2025-04-01 | — | — | US | disclosed |
| US-12178064-B2 | Materials for forming a nucleation-inhibiting coating and devices incorporating same | OTI LUMIONICS INC. (CA) | 2024-12-24 | — | — | US | disclosed |
| EP-4063368-B1 | NITROGEN-CONTAINING COMPOUND AND ELECTRONIC ELEMENT COMPRISING SAME, AND ELECTRONIC APPARATUS | SHAANXI LIGHTE OPTOELECTRONICS MAT CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| US-20230363196-A1 | MATERIALS FOR FORMING A NUCLEATION-INHIBITING COATING AND DEVICES INCORPORATING SAME | OTI LUMIONICS INC. (CA) | 2023-11-09 | — | — | US | disclosed |
| US-11751415-B2 | Materials for forming a nucleation-inhibiting coating and devices incorporating same | OTI LUMIONICS INC. (CA) | 2023-09-05 | — | — | US | disclosed |
| US-20230247903-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS INCLUDING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| US-20230247903-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS INCLUDING SAME | SHAANXI LIGHTE OPTOELECTRONICS MATERIAL CO., LTD. (CN) | 2023-08-03 | — | — | US | disclosed |
| EP-3741757-B1 | DIHYDROINDOLIZINONE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2023-07-26 | — | — | EP | disclosed |
| EP-4198020-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE COMPRISING SAME, AND ELECTRONIC APPARATUS | Shaanxi Lighte Optoelectronics Material Co., Ltd. (CN) | 2023-06-21 | — | — | EP | disclosed |
| EP-1311505-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE ( NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS ) | PHARMACIA & UPJOHN COMPANY (US) | 2003-05-21 | — | — | EP | disclosed |
| WO-2003022842-A1 | THIOPHENYLTHIOPYRANE DIOXIDES AS MMP OR TNF-ALPHA INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-20 | — | — | WO | disclosed |
| US-6500840-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-31 | — | — | US | disclosed |
| US-6492385-B2 | CENTRAL NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY GLOBAL INTELLECTUAL PROPERTY | 2002-07-11 | — | — | US | disclosed |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2002-04-11 | — | — | US | disclosed |
| WO-2002015662-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002017358-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC ACETYLCHOLINE RECEPTOR ANTAGONISTS) | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002016355-A2 | QUINUCLIDINE-SUBSTITUTED HETEROARYL MOIETIES FOR TREATMENT OF DISEASE (NICOTINIC) ACETYLCHOLINE RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12268092-B2 | Photoelectric conversion element, imaging element, optical sensor, material for photoelectric conversion element, and compound | NCS1, CRY1, PIEZO1 | CA2 1233/4885LPL 2842/4885LIPG 2247/4885 |
| US-20230247903-A1 | ORGANIC COMPOUND, ORGANIC ELECTROLUMINESCENT DEVICE AND ELECTRONIC APPARATUS INCLUDING SAME | OR10J3, ODC1, ORC3 | CA2 3261/4885LPL 1012/4885LIPG 1127/4885 |
| US-20020042428-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | CA2 2583/4885LPL 2889/4885LIPG 1926/4885 |
| US-20020042429-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | PARK7, CYP3A7, UGT2B7 | CA2 2182/4885LPL 2861/4885LIPG 1670/4885 |
| US-20020091135-A1 | Quinuclidine-substituted heteroaryl moieties for treatment of disease | NQO2, GBA1, UGT1A1 | CA2 2583/4885LPL 2889/4885LIPG 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.